TABLE 5.
Off‐target pharmacological profiling of ELP‐004 [10 μM] with >10% inhibition.
| Radioligand assays | Concentration (M) | % of inhibition | Reference compound |
|---|---|---|---|
| A1 (h) (antagonist) | 1.0E‐05 | 21.9 | DPCPX |
| CCK1 (CCKA) (h) (agonist) | 1.0E‐05 | 10.3 | CCK‐8s |
| CCR1 (h) (agonist) | 1.0E‐05 | 16.2 | MIP‐1α |
| MT1 (ML1A) (h) (agonist radioligand) | 1.0E‐05 | 25.8 | Melatonin |
| Kappa (KOP) (agonist) | 1.0E‐05 | 15.2 | U 50488 |
| 5‐HT1A (h) (agonist) | 1.0E‐05 | 20.7 | 8‐OH‐DPAT |
| 5‐HT2B (h) (agonist) | 1.0E‐05 | 23 | (±)DOI |
| 5‐HT3 (h) (antagonist) | 1.0E‐05 | 12.4 | MDL 72222 |
| Dopamine transporter (h) (antagonist) | 1.0E‐05 | 82.2 | BTCP |
Note: Data are presented as mean values; n = 2. The results are expressed as percent inhibition of control‐specific binding.
Abbreviation: h, human.